Company intelligence / Profile preview

Lactocore

Plymouth, Michigan, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Lactocore's lead peptide program (LCGA-17) is advancing toward Phase 1 trials for anxiety disorders after promising preclinical animal data in stress and behavioral models. Another asset, CHM-273, has shown efficacy in animal models of metabolic disease, affecting insulin resistance and inflammation. All pipeline assets are currently preclinical or at discovery/IND-enabling stage; no clinical results in humans have been reported yet.

Therapeutic areas: NeurologyMetabolic DisordersPsychiatry
Modalities: PeptidesSynthetic peptideSmall molecule
Industry: Biotech

Partnerships

Ingredia (French dairy company, for functional food ingredients and R&D collaboration)Centre for Human Drug Research (Netherlands, for clinical biomarker studies)

Beyond the preview

Go deeper on Lactocore.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactocore.

Explore the full profile